Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
// Andrea Botticelli 2,* , Ilaria Zizzari 1,* , Federica Mazzuca 2 , Paolo Antonio Ascierto 4 , Lorenza Putignani 3 , Luca Marchetti 5 , Chiara Napoletano 1 , Marianna Nuti 1,* and Paolo Marchetti 2,* 1 Department of Experimental Medicine, “Sapienza University of Rome, Rome, Italy 2 Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, Italy 3 Units of Parasitology and Human Microbiome, Bambino Gesù Children’s Hospital and Research Institute, Rome, Italy 4 Melanoma, Cancer Immunotherapy, and Innovative Therapy, Istituto nazionale Tumori Fondazione “G Pascale”, Napoli, Italy 5 Department of Clinical Oncology, Policlinico Umberto I, University of Rome Sapienza, Rome, Italy Correspondence to: Marianna Nuti, email: // * These authors have contributed equally to this work Keywords : microbiome, immunotherapy, PD-1, PDL-1, CTLA-4 Received : July 18, 2016 Accepted : October 13, 2016 Published : October 28, 2016 Abstract Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“In particular Sivan et al compared melanoma growth in mice derived from two different mouse facilities (JAX and TAC) harboring different intestinal microbiota but genetically similar [81].”
BackgroundRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“Currently different monoclonal anti PD-1 and anti-PD-L1 antibodies are in development for the treatment of advanced disease; they include Nivolumab (OPDIVO, anti-PD 1) [16-23], Pembrolizumab (Keytruda, anti-PD-1) [24-34], Atezolizumab (anti PD-L1)[35-36] ,”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“[65] demonstrated that germ free or antiobiotics treated mice had poor benefit from anti-CTLA-4 therapy and showed also that anti-CTLA-4 therapy can modify the composition of microbiota.”
BackgroundFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · cited 1×
“Currently different monoclonal anti PD-1 and anti-PD-L1 antibodies are in development for the treatment of advanced disease; they include Nivolumab (OPDIVO, anti-PD 1) [16-23], Pembrolizumab (Keytruda, anti-PD-1) [24-34], Atezolizumab (anti PD-L1)[35-36] ,”
BackgroundSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“The response is maintained for a long time after the end of the treatment and long time survivors up to ten years and cured patients are now a reality [6] .”
BackgroundImmune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 1×
“The new side effects described for ICI treatments are in fact mainly immune related and autoimmunity classified, distinct from chemo and molecular targeted therapy and they have challenged greatly medical oncologists [8] .”
BackgroundThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960
Innate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921 · cited 1×
“[43-48] The close association between cancer susceptibility [49-61], responsiveness to cancer therapy and microbiome has just been investigated.”
Background
Cited by
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
“Besides, PD-L1 is also widely expressed in lymphatic and non-lymphatic tissues [38].”
BackgroundMitra, A., Grossman Biegert, G. W., Delgado, A. Y., Karpinets, T. V., Solley, T. N., Mezzari, M. P., Yoshida-Court, K., Petrosino, J. F., Mikkelson, M. D., Lin, L., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.040 · Cited by 90
Huang, P., Wang, X., Wang, S., Wu, Z., Zhou, Z., Shao, G., Ren, C., Kuang, M., Zhou, Y., Jiang, A., et al. (2022) · Current Research in Food Science · doi:10.1016/j.crfs.2022.08.011 · Cited by 43
“Also, the existence of a “Cross-Talk” between intestinal microbiota and intestinal mucosal immune response revealed that the prognosis of IBD can’t be explained only by activating or inhibiting one pathway and increasing or decreasing some kinds of bacterium (Botticelli et al., 2017; Schroeder and Bäckhed, 2016).”
Background
Metadata
- Authors
- Botticelli, A., Zizzari, I., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-28
- Volume
- 8
- Issue
- 5
- Pages
- 8890-8899
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2545600439
- Cited by
- 56
- References
- 24
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.